HC Wainwright Estimates Liquidia FY2026 Earnings

Liquidia Corporation (NASDAQ:LQDA – Free Report) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Liquidia in a research report issued on Friday, November 13th. HC Wainwright analyst M. Caufield anticipates that the company will earn $3.33 per share for the year. HC Wainwright currently has a “Buy” rating and a $76.00 target price on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Liquidia’s Q4 2026 earnings at $0.96 EPS, FY2027 earnings at $3.09 EPS, FY2028 earnings at $3.18 EPS, FY2029 earnings at $3.58 EPS and FY2030 earnings at $3.62 EPS.

Other equities analysts have also issued reports about the stock. Piper Sandler set a $129.00 price target on shares of Liquidia in a research note on Friday, July 24th. Zacks Research upgraded shares of Liquidia from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 12th. Wall Street Zen cut shares of Liquidia from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Wells Fargo & Company increased their target price on shares of Liquidia from $33.00 to $40.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 11th. Finally, Royal Bank Of Canada set a $65.00 target price on shares of Liquidia in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $75.23.

Read Our Latest Analysis on LQDA

Liquidia Price Performance

LQDA stock opened at $56.37 on Tuesday. The business has a 50 day moving average price of $48.72 and a 200 day moving average price of $54.82. The stock has a market cap of $5.08 billion, a price-to-earnings ratio of -45.83, a PEG ratio of 1.39 and a beta of 0.40. Liquidia has a fifty-two week low of $22.31 and a fifty-two week high of $93.61. The company has a quick ratio of 2.12, a current ratio of 1.02 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($2.64) EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($3.60). Liquidia had a negative net margin of 15.15% and a positive return on equity of 264.65%. The business had revenue of $225.30 million during the quarter, compared to analysts’ expectations of $214.18 million. During the same quarter in the previous year, the company posted ($0.04) EPS. The company’s revenue was up 314.9% compared to the same quarter last year.

Insider Transactions at Liquidia

In related news, insider Jason Adair sold 688 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $43.19, for a total transaction of $29,714.72. Following the transaction, the insider owned 177,269 shares in the company, valued at $7,656,248.11. This trade represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Scott Moomaw sold 8,863 shares of Liquidia stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $252,418.24. Following the transaction, the insider directly owned 181,487 shares in the company, valued at approximately $5,168,749.76. This trade represents a 4.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 537,045 shares of company stock worth $23,476,727. Insiders own 25.60% of the company’s stock.

Hedge Funds Weigh In On Liquidia

Hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC increased its holdings in shares of Liquidia by 13.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,634 shares of the company’s stock valued at $80,000 after acquiring an additional 320 shares during the period. Pinnacle Wealth Planning Services Inc. raised its position in Liquidia by 26.2% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,557 shares of the company’s stock valued at $47,000 after purchasing an additional 323 shares during the last quarter. Hanseatic Management Services Inc. raised its position in Liquidia by 2.0% in the 3rd quarter. Hanseatic Management Services Inc. now owns 21,733 shares of the company’s stock valued at $658,000 after purchasing an additional 435 shares during the last quarter. Quantinno Capital Management LP raised its position in Liquidia by 3.6% in the 1st quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after purchasing an additional 589 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its stake in Liquidia by 4.4% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 16,700 shares of the company’s stock worth $505,000 after purchasing an additional 700 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.

See Also

Earnings History and Estimates for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.